West Pharmaceutical Services (WST) Projected to Post Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) will likely be posting its quarterly earnings results before the market opens on Thursday, February 13th. Analysts expect West Pharmaceutical Services to post earnings of $1.71 per share and revenue of $740.87 million for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

West Pharmaceutical Services Trading Up 0.8 %

Shares of West Pharmaceutical Services stock opened at $324.25 on Tuesday. The firm’s 50 day simple moving average is $332.34 and its two-hundred day simple moving average is $314.81. The firm has a market capitalization of $23.48 billion, a price-to-earnings ratio of 48.11, a PEG ratio of 19.31 and a beta of 1.01. West Pharmaceutical Services has a 12-month low of $265.00 and a 12-month high of $409.72. The company has a current ratio of 3.00, a quick ratio of 2.23 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 11th. Investors of record on Friday, February 7th will be paid a $0.21 dividend. The ex-dividend date is Friday, February 7th. This represents a $0.84 dividend on an annualized basis and a yield of 0.26%. West Pharmaceutical Services’s dividend payout ratio (DPR) is 12.46%.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on WST shares. Wolfe Research started coverage on West Pharmaceutical Services in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. Citigroup initiated coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 8th. They set a “buy” rating and a $400.00 target price for the company. Bank of America boosted their target price on shares of West Pharmaceutical Services from $350.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, December 13th. StockNews.com raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, UBS Group raised shares of West Pharmaceutical Services from a “neutral” rating to a “buy” rating and raised their price target for the stock from $350.00 to $390.00 in a research note on Thursday, December 12th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $403.75.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.